It is interesting that getting naive patients for inclusion in the mtnbc trial is not that important, getting as many cancer patients as possible is. I think any partner is looking at the data as a whole and the FDA trial and approval as not a problem. The 25-30 patients that want this drug for their cancer is great for us, mostly for them!